Sarepta Therapeutics Company Profile (NASDAQ:SRPT)

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its quarterly earnings results on Wednesday, July, 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.46. The firm earned $35.01 million during the quarter, compared to the consensus estimate of $22.52 million. The firm's revenue was up 350000.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.19) EPS. View Sarepta Therapeutics' Earnings History.

20 equities research analysts have issued twelve-month price targets for Sarepta Therapeutics' shares. Their forecasts range from $27.00 to $96.00. On average, they anticipate Sarepta Therapeutics' share price to reach $62.50 in the next year. View Analyst Ratings for Sarepta Therapeutics.

Here are some recent quotes from research analysts about Sarepta Therapeutics stock:

• 1. According to Zacks Investment Research, "Sarepta has received a huge boost with the FDA approval of Exondys 51, the first DMD treatment to gain approval in the U.S. Also, a marketing application is under review in the EU, which if approved, should augment sales. Moreover, the company’s collaboration agreements with Summit Pharmaceuticals and Catabasis as well as its own follow-on exon-skipping pipeline candidates represent the most comprehensive approach to treat DMD. Sarepta’s shares have outperformed the industry in the last one year. However, Exondys 51’s commercial launch has been slower than expected due to slow patient starts and reimbursement hurdles. However, Sarepta expects a pickup in patient starts and conversion rates as 2017 progresses. Meanwhile, competition in the RNA-based treatment market remains a threat. Estimates have remained mostly stable ahead of the Q2 results. Sarepta has a mixed record of earnings surprises in the recent quarters." (7/17/2017)
• 2. Cowen and Company analysts commented, "SRPT reported 1Q17 results, including a slight Exondys 51 beat and raise; we see." (4/28/2017)
• 3. Instinet analysts commented, "We are initiating coverage on Sarepta Therapeutics (SRPT) with a Buy rating and $84 target price. We recommend owning SRPT shares, expecting significant upside to materialize as Exondys 51 launch metrics begin to reflect an underestimated demand for the treatment and the ultimate patient numbers/market opportunity. We expect additional upside to be realized following EU approval of Exondys 51, which will help bolster perception of the drug's benefit and to define the EU opportunity, currently not reflected in shares." (3/1/2017)
• 4. Needham & Company LLC analysts commented, "As previously reported, Sarepta earned $5.4M in 4Q16 Exondys revenue. The company gave 1Q and FY17 guidance for Exondys sales of $13-15M and >$80M, respectively. While the 1Q guidance number is relatively in line with our ($17M) and the Street's estimates, the low end of FY17 guidance is significantly below expectations and implies no acceleration in new patient starts through the back part of 2017. This sales guidance contrasts with management's qualitative commentary about accelerating conversion rates and we believe is explained by conservatism in an uncertain and dynamic reimbursement environment. We continue to expect that the majority of the 1,400+ eligible DMD boys in the US will ultimately be on therapy by implying a ~$400M Exondys US sales run rate." (3/1/2017)
• 5. Royal Bank Of Canada analysts commented, "Sarepta provided sales guidance for EXONDYS 51 on tonight's call, which clearly disappointed investors (SRPT -15%AH). We didn't hear anything on the call to justify this level of selling: while FY17 guidance appears soft to us (>$80M) and doesn't exude confidence, guidance for 1Q17 ($13-$15 vs. $5.4M in 4Q16) and management's language about conversion rate acceleration, makes us view the >$80M guidance as beatable." (3/1/2017)

Some companies that are related to Sarepta Therapeutics include Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), BeiGene (BGNE), GW Pharmaceuticals PLC (GWPH), Agios Pharmaceuticals (AGIO), China Biologic Products (CBPO), Prothena Corporation PLC (PRTA), Axovant Sciences Ltd (AXON), AveXis (AVXS), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Loxo Oncology (LOXO), Radius Health (RDUS) and Lexicon Pharmaceuticals (LXRX).

Sarepta Therapeutics' management team includes the folowing people:

• Douglas S. Ingram, President, Chief Executive Officer
• Sandesh Mahatme, Executive Vice President, Chief Financial Officer and Chief Business Officer
• David Tyronne Howton Jr., Senior Vice President, General Counsel, Corporate Secretary
• Alexander Cumbo, Senior Vice President, Global Commercial Development
• Shamim Ruff, Senior Vice President - Regulatory Affairs and Quality
• Catherine Stehman-Breen M.D., Senior Vice President, Chief Medical Officer
• Richard J. Barry, Independent Director
• M. Kathleen Behrens Ph.D., Independent Director
• Claude Nicaise M.D., Independent Director
• Hans Wigzell M.D., Ph.D., Independent Director

Sarepta Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Creative Planning (0.19%), Bank of Montreal Can (0.18%), Sit Investment Associates Inc. (0.04%), Private Capital Advisors Inc. (0.03%), Carl Domino Inc (0.02%) and Legato Capital Management LLC (0.01%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Edward M Md Kaye, Jayant Aphale, M Kathleen Behrens, Sandesh Mahatme and Shamim Ruff. View Institutional Ownership Trends for Sarepta Therapeutics.

Sarepta Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have sold Sarepta Therapeutics stock in the last year include Alexander Cumbo, David T Howton, Edward M Md Kaye, Jayant Aphale, Sandesh Mahatme and Shamim Ruff. View Insider Buying and Selling for Sarepta Therapeutics.

Sarepta Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Sit Investment Associates Inc., Private Capital Advisors Inc., Legato Capital Management LLC and Prentiss Smith & Co. Inc.. View Insider Buying and Selling for Sarepta Therapeutics.

Shares of Sarepta Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Sarepta Therapeutics stock can currently be purchased for approximately $43.95.